Aarey Drugs Q1 FY27 Unaudited Results: Profit Declines to ₹1.02 Crore
Aarey Drugs & Pharmaceuticals Limited reported unaudited Q1 FY27 results with a profit of ₹1.02 crore, down from ₹1.37 crore year-on-year. Total income was ₹463.40 lakhs. The company also confirmed no deviation in the utilization of funds raised via preferential issue during the quarter. Trading window to reopen post-announcement.
The results show a year-on-year decline in profitability and revenue, which could impact investor sentiment and the company's stock performance. However, the absence of deviation in fund utilization is a neutral factor.
The company reported a decline in profit and total income compared to the same quarter last year, indicating a negative financial performance trend.
Aarey Drugs & Pharmaceuticals Limited announced its unaudited financial results for the first quarter ended June 30, 2026. The company's Board of Directors considered and approved these results, along with the Limited Review Report and MD/CFO certification, during a meeting held on August 14, 2026.
The financial results indicate a profit after tax of ₹1.02 crore for the quarter. This compares to a profit of ₹1.37 crore for the corresponding quarter in the previous year (June 30, 2025). The company also reported total income of ₹463.40 lakhs for the current quarter, a decrease from ₹1037.60 lakhs in the same period last year. Expenses for the quarter were ₹458.25 lakhs.
The board also reviewed and approved the Statement of Deviation or Variation in Utilization of Funds Raised through Convertible Warrants (Preferential Issue). The company had raised ₹797.50 lakhs through this route on May 23, 2025. While 25% of the consideration was received and utilized at the time of allotment, the remaining 75% is receivable upon exercise of warrants. No further funds were received or utilized during the quarter ended June 30, 2026, thus the statement of deviation or variation for this quarter was filed as Nil.
In compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for the company will reopen 48 hours after the announcement of these results. The board meeting commenced at 5:00 p.m. and concluded at 7:00 p.m.
What to do with a filing like this
Aarey Drugs & Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Aarey Drugs & Pharmaceuticals Limited. Read the original for the full detail.